GeoVax Labs (GOVX) Stock Forecast, Price Target & Predictions
GOVX Stock Forecast
GeoVax Labs stock forecast is as follows: an average price target of $8.00 (represents a 193.04% upside from GOVX’s last price of $2.73) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
GOVX Price Target
The average price target for GeoVax Labs (GOVX) is $8.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 193.04% upside from GOVX's last price of $2.73.
GOVX Analyst Ratings
According to 4 Wall Street analysts, GeoVax Labs's rating consensus is 'Buy'. The analyst rating breakdown for GOVX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
GeoVax Labs Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 02, 2024 | Vernon Bernardino | H.C. Wainwright | $8.00 | $3.28 | 143.90% | 193.04% |
The latest GeoVax Labs stock forecast, released on Jul 02, 2024 by Vernon Bernardino from H.C. Wainwright, set a price target of $8.00, which represents a 143.90% increase from the stock price at the time of the forecast ($3.28), and a 193.04% increase from GOVX last price ($2.73).
GeoVax Labs Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $8.00 | $8.00 |
| Last Closing Price | $2.73 | $2.73 | $2.73 |
| Upside/Downside | -100.00% | 193.04% | 193.04% |
In the current month, the average price target of GeoVax Labs stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to GeoVax Labs's last price of $2.73. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 19, 2024 | Noble Capital Markets | Outperform | Outperform | Hold |
| Jul 23, 2024 | EF Hutton | - | Buy | Initialise |
| Jun 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 24, 2022 | Maxim Group | Buy | Buy | Hold |
GeoVax Labs's last stock rating was published by Noble Capital Markets on Aug 19, 2024. The company gave GOVX a "Outperform" rating, the same as its previous rate.
GeoVax Labs Financial Forecast
GeoVax Labs Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $103.91K | - | $251.62K | $268.51K | $333.21K | $209.94K | $638.00K |
| Avg Forecast | $41.70M | $37.23M | $35.75M | $34.26M | $514.37M | $12.83M | $12.32M | $11.80M | $918.75K | $918.75K | $300.68K | - | $103.91K | $596.53K | $400.00K | $300.00K | $300.00K | $300.00K | $638.00K |
| High Forecast | $41.70M | $37.23M | $35.75M | $34.26M | $514.37M | $12.83M | $12.32M | $11.80M | $918.75K | $938.72K | $300.68K | - | $103.91K | $715.84K | $400.00K | $300.00K | $300.00K | $300.00K | $765.60K |
| Low Forecast | $41.70M | $37.23M | $35.75M | $34.26M | $514.37M | $12.83M | $12.32M | $11.80M | $918.75K | $898.78K | $300.68K | - | $103.91K | $477.22K | $400.00K | $300.00K | $300.00K | $300.00K | $510.40K |
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 18 | 10 | 8 | 8 | 11 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | - | 0.63% | 0.90% | 1.11% | 0.70% | 1.00% |
GeoVax Labs's average Quarter revenue forecast for Mar 24 based on 1 analysts is -, with a low forecast of -, and a high forecast of -. GOVX's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $103.91K (Dec 23).
GeoVax Labs EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 18 | 10 | 8 | 8 | 11 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-25.97T | $-3.95M | $-1.32M | $-586.72K | $-421.48K | $-651.16K | $-273.37K |
| Avg Forecast | $-25.02M | $-22.34M | $-21.45M | $-20.55M | $-308.62M | $-7.70M | $-7.39M | $-7.08M | $-551.25K | $-551.25K | $-180.41K | - | $-62.35K | $-340.80K | $-240.00K | $-180.00K | $-180.00K | $-631.22K | $-364.49K |
| High Forecast | $-25.02M | $-22.34M | $-21.45M | $-20.55M | $-308.62M | $-7.70M | $-7.39M | $-7.08M | $-551.25K | $-539.27K | $-180.41K | - | $-62.35K | $-272.64K | $-240.00K | $-180.00K | $-180.00K | $-504.98K | $-291.59K |
| Low Forecast | $-25.02M | $-22.34M | $-21.45M | $-20.55M | $-308.62M | $-7.70M | $-7.39M | $-7.08M | $-551.25K | $-563.23K | $-180.41K | - | $-62.35K | $-408.96K | $-240.00K | $-180.00K | $-180.00K | $-757.47K | $-437.39K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 416487456.41% | 11.59% | 5.50% | 3.26% | 2.34% | 1.03% | 0.75% |
undefined analysts predict GOVX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than GeoVax Labs's previous annual EBITDA (undefined) of $NaN.
GeoVax Labs Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 18 | 10 | 8 | 8 | 11 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-25.97T | $-3.97M | $-1.34M | $-590.59K | $-424.43K | $-654.15K | $-296.78K |
| Avg Forecast | - | - | - | - | - | - | - | - | $-2.26M | $-3.75M | $-8.55M | $-13.16M | $-5.45M | $-369.98K | $-1.18M | $-612.77B | $-954.50B | $-634.12K | $-395.70K |
| High Forecast | - | - | - | - | - | - | - | - | $-2.26M | $-2.65M | $-8.55M | $-13.16M | $-5.45M | $-295.99K | $-1.18M | $-612.77B | $-954.50B | $-507.30K | $-316.56K |
| Low Forecast | - | - | - | - | - | - | - | - | $-2.26M | $-4.68M | $-8.55M | $-13.16M | $-5.45M | $-443.98K | $-1.18M | $-612.77B | $-954.50B | $-760.95K | $-474.85K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 4761607.18% | 10.72% | 1.13% | 0.00% | 0.00% | 1.03% | 0.75% |
GeoVax Labs's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GOVX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
GeoVax Labs SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 18 | 10 | 8 | 8 | 11 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $6.02T | $1.25M | $831.36K | $423.49K | $291.48K | $412.65K | $334.17K |
| Avg Forecast | $621.01M | $554.47M | $532.29M | $510.11M | $7.66B | $191.05M | $183.41M | $175.77M | $13.68M | $13.68M | $4.48M | - | $1.55M | $416.59K | $5.96M | $4.47M | $4.47M | $4.47M | $445.55K |
| High Forecast | $621.01M | $554.47M | $532.29M | $510.11M | $7.66B | $191.05M | $183.41M | $175.77M | $13.68M | $13.98M | $4.48M | - | $1.55M | $499.91K | $5.96M | $4.47M | $4.47M | $4.47M | $534.66K |
| Low Forecast | $621.01M | $554.47M | $532.29M | $510.11M | $7.66B | $191.05M | $183.41M | $175.77M | $13.68M | $13.38M | $4.48M | - | $1.55M | $333.27K | $5.96M | $4.47M | $4.47M | $4.47M | $356.44K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3891858.50% | 3.00% | 0.14% | 0.09% | 0.07% | 0.09% | 0.75% |
GeoVax Labs's average Quarter SG&A projection for Mar 24 is -, based on 1 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to GOVX last annual SG&A of $6.02T (Dec 23).
GeoVax Labs EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 18 | 10 | 8 | 8 | 11 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-14.29 | $-0.17 | $-0.25 | $-2.52 | $-177.59 | $-32.71K | $-0.43 |
| Avg Forecast | - | - | - | - | - | - | - | - | $-0.89 | $-1.48 | $-3.37 | $-5.56 | $-2.78 | $-1.80 | $-0.60 | $-312.00K | $-486.00K | $-588.00K | $-40.00K |
| High Forecast | - | - | - | - | - | - | - | - | $-0.89 | $-1.04 | $-3.37 | $-5.56 | $-2.78 | $-1.80 | $-0.60 | $-312.00K | $-486.00K | $-588.00K | $-32.00K |
| Low Forecast | - | - | - | - | - | - | - | - | $-0.89 | $-1.84 | $-3.37 | $-5.56 | $-2.78 | $-1.80 | $-0.60 | $-312.00K | $-486.00K | $-588.00K | $-48.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 5.15% | 0.09% | 0.42% | 0.00% | 0.00% | 0.06% | 0.00% |
According to undefined Wall Street analysts, GeoVax Labs's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GOVX previous annual EPS of $NaN (undefined).
GeoVax Labs Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| BWV | Onconetix | $0.18 | $4.00 | 2122.22% | Buy |
| ONTX | Traws Pharma | $1.00 | $7.00 | 600.00% | Buy |
| OCGN | Ocugen | $1.12 | $5.00 | 346.43% | Buy |
| ATXI | Avenue Therapeutics | $2.76 | $12.00 | 334.78% | Buy |
| GOVX | GeoVax Labs | $2.73 | $8.00 | 193.04% | Buy |
| ZURA | Zura Bio | $3.88 | $5.00 | 28.87% | Buy |
GOVX Forecast FAQ
Is GeoVax Labs a good buy?
Yes, according to 4 Wall Street analysts, GeoVax Labs (GOVX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of GOVX's total ratings.
What is GOVX's price target?
GeoVax Labs (GOVX) average price target is $8 with a range of $8 to $8, implying a 193.04% from its last price of $2.73. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will GeoVax Labs stock go up soon?
According to Wall Street analysts' prediction for GOVX stock, the company can go up by 193.04% (from the last price of $2.73 to the average price target of $8), up by 193.04% based on the highest stock price target, and up by 193.04% based on the lowest stock price target.
Can GeoVax Labs stock reach $4?
GOVX's average twelve months analyst stock price target of $8 supports the claim that GeoVax Labs can reach $4 in the near future.
What are GeoVax Labs's analysts' financial forecasts?
GeoVax Labs's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $551.32M (high $551.32M, low $551.32M), average EBITDA is $-331M (high $-331M, low $-331M), average net income is $0 (high $0, low $0), average SG&A $8.21B (high $8.21B, low $8.21B), and average EPS is $0 (high $0, low $0). GOVX's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $148.94M (high $148.94M, low $148.94M), average EBITDA is $-89.363M (high $-89.363M, low $-89.363M), average net income is $0 (high $0, low $0), average SG&A $2.22B (high $2.22B, low $2.22B), and average EPS is $0 (high $0, low $0).
Did the GOVX's actual financial results beat the analysts' financial forecasts?
Based on GeoVax Labs's last annual report (Dec 2020), the company's revenue was $1.82M, beating the average analysts forecast of $400K by 355.75%. Apple's EBITDA was $-2.817M, beating the average prediction of $-240K by 1073.75%. The company's net income was $-2.936M, beating the average estimation of $-1.178M by 149.14%. Apple's SG&A was $2.2M, missing the average forecast of $5.96M by -63.13%. Lastly, the company's EPS was $-2.12, beating the average prediction of $-0.6 by 253.33%. In terms of the last quarterly report (Dec 2023), GeoVax Labs's revenue was $103.91K, beating the average analysts' forecast of $103.91K by 0%. The company's EBITDA was $-25.967T, beating the average prediction of $-62.347K by 41648745541.04%. GeoVax Labs's net income was $-25.967T, beating the average estimation of $-5.453M by 476160618.22%. The company's SG&A was $6.02T, beating the average forecast of $1.55M by 389185749.99%. Lastly, the company's EPS was $-14.29, beating the average prediction of $-2.777 by 414.65%